Quoin Pharmaceuticals, Ltd. (QNRX) — SEC Filings
Quoin Pharmaceuticals, Ltd. (QNRX) — 50 SEC filings. Latest: 10-Q (May 7, 2026). Includes 35 8-K, 7 10-Q, 2 DEF 14A.
View Quoin Pharmaceuticals, Ltd. on SEC EDGAR
Overview
Quoin Pharmaceuticals, Ltd. (QNRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Quoin Pharmaceuticals, Ltd. filed an 8-K on March 26, 2026, reporting under Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financial Statements and Exhibits." This filing indicates the company is likely disclosing recent financial performance or significant operational u
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Quoin Pharmaceuticals, Ltd. is neutral.
Filing Type Overview
Quoin Pharmaceuticals, Ltd. (QNRX) has filed 7 10-Q, 35 8-K, 2 DEF 14A, 2 10-K, 1 S-1/A, 1 S-1, 1 SC 13G/A, 1 DEFA14A with the SEC between Mar 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of QNRX's 46 recent filings, 4 were flagged as high-risk, 26 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$11.46M |
| EPS | -$19.50 |
| Cash Position | $1.83M |
| Total Assets | $6.42M |
Key Executives
- Dr. Michael Myers
- Dr. Yossi Gross
- Mr. Eyal Lifschitz
- Peter I. Tsoflias
- Melissa Palat Murawsky
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Quoin Pharmaceuticals often operate at a loss for extended periods, relying on substantial capital infusions to fund drug discovery and clinical trials. The competitive landscape is intense, with established players and emerging biotechs vying for market share and investor capital.
Top Tags
8-K (10) · pharmaceuticals (7) · financials (7) · regulatory-filing (7) · filing (6) · corporate-governance (5) · financial-reporting (5) · company-update (4) · 10-Q (4) · corporate-action (4)
Executive Compensation
From the most recent DEF 14A filing (Jul 17, 2025):
- Dr. Michael Myers — Chairman of the Board of Directors and Chief Executive Officer
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $11.46M | Increased from $6.65M for the nine months ended September 30, 2024, a 72.3% increase. |
| Research and Development Expenses | $6.71M | More than doubled from $2.55M for the nine months ended September 30, 2024. |
| Cash and Cash Equivalents | $1.83M | Decreased from $3.62M at December 31, 2024. |
| Accumulated Deficit | $66.62M | Increased from $55.17M at December 31, 2024. |
| Net Cash Used in Operating Activities | $8.51M | Increased from $5.62M for the nine months ended September 30, 2024. |
| Gross Proceeds from Private Placement | $16.6M | Secured on October 10, 2025, providing crucial liquidity. |
| Proceeds from Warrant Exercises | $3.3M | Received on October 14, 2025, further bolstering cash reserves. |
| Ordinary Shares Outstanding | 20,585,830 | As of September 30, 2025, up from 8,948,164 at December 31, 2024, indicating significant dilution. |
| Revenue | $0 | No revenue for Q2 2025 and YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | -$3.5M | Represents a narrower loss compared to -$4.2M in Q2 2024. |
| Net Loss (YTD 2025) | -$7.1M | Represents a narrower loss compared to -$8.5M in YTD 2024. |
| R&D Expenses (Q2 2025) | $2.1M | Decreased from $2.8M in Q2 2024, contributing to reduced net loss. |
| R&D Expenses (YTD 2025) | $4.3M | Decreased from $5.6M in YTD 2024, reflecting cost management. |
| G&A Expenses (Q2 2025) | $1.4M | Slight increase from $1.3M in Q2 2024. |
| Filing Date | 2025-07-17 | Date the DEF 14A was filed with the SEC |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Quoin Pharmaceuticals, Ltd. (QNRX)?
Quoin Pharmaceuticals, Ltd. has 50 recent SEC filings from Mar 2024 to May 2026, including 35 8-K, 7 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QNRX filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Quoin Pharmaceuticals, Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Quoin Pharmaceuticals, Ltd. (QNRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Quoin Pharmaceuticals, Ltd.?
Key financial highlights from Quoin Pharmaceuticals, Ltd.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QNRX?
The investment thesis for QNRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Quoin Pharmaceuticals, Ltd.?
Key executives identified across Quoin Pharmaceuticals, Ltd.'s filings include Dr. Michael Myers, Dr. Yossi Gross, Mr. Eyal Lifschitz, Peter I. Tsoflias, Melissa Palat Murawsky.
What are the main risk factors for Quoin Pharmaceuticals, Ltd. stock?
Of QNRX's 46 assessed filings, 4 were flagged high-risk, 26 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Quoin Pharmaceuticals, Ltd.?
Forward guidance and predictions for Quoin Pharmaceuticals, Ltd. are extracted from SEC filings as they are enriched.